Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells

Experimental and Molecular Pathology

Volumn 88, Issue 3, 2010, Pages 401-406

  Guo, Linlang ^a   Chen, Pinglian ^a   Zhou, Yuanyuan ^a   Sun, Yanqin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Bcl XL; Etk; P53; Small cell lung cancer

Indexed keywords

DOXORUBICIN; EPITHELIAL AND ENDOTHELIAL TYROSINE KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; BCL2L1 PROTEIN, HUMAN; BMX PROTEIN, HUMAN; PROTEIN BCL X; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; PROTEIN EXPRESSION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DOXORUBICIN; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952564029     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.02.003     Document Type: Article

References (23)

1. Biswas S.K., Huang J., Persaud S., Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol. Cancer Ther. 2004, 3:327-334.
2. Chen E.K., Huang L.M., Kung H.J., Ann D.K., Shih H.M. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene 2004, 23:1854-1862.
3. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J. Clin. Oncol. 1999, 17:1794-1801.
4. Eerola A.K., Tormanen U., Rainio P., Sormunen R., Bloigu R., Vähäkangas K., Lehto V.P., Soini Y., Pääkkö P. Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. J. Pathol. 1997, 181:172-177.
5. Ekman N., Arighi E., Rajantie I., Saharinen P., Ristimaki A., Silvennoinen O., Alitalo K. The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene 2000, 19:4151-4158.
6. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
7. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., Spitznagel E.L., Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24:4539-4544.
8. Harada T., Ogura S., Yamazaki K., Kinoshita I., Itoh T., Isobe H., Yamashiro K., Dosaka-Akita H., Nishimura M. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003, 94:394-399.
9. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
10. Jiang T., Guo Z., Dai B., Kang M., Ann D.K., Kung H.J. Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J. Biol. Chem. 2004, 279:50181-50189.
11. Kaiser U., Schilli M., Haag U., Neumann K., Kreipe H., Kogan E., Havemann K. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996, 15:31-40.
12. Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 1999, 10:267-280.
13. Qiu Y., Kung H.J. Signaling network of the Btk family kinases. Oncogene 2000, 19:5651-5661.
14. Rickardson L., Fryknas M., Dhar S., Lövborg H., Gullbo J., Rydåker M., Nygren P., Gustafsson M.G., Larsson R., Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 2005, 93:483-492.
15. Robinson D., He F., Pretlow T., Kung H.J. A tyrosine kinase profile of prostate carcinoma. PNAS 1996, 93:5958-5962.
16. Rudin C.M., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B., George C.M., Szeto L., Vokes E.E. A pilot trial of G3139, a bcl-2 antiense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 2002, 13:539-545.
17. Sandler A.B. Chemotherapy for small cell lung cancer. Semin. Oncol. 2003, 30:9-25.
18. Shivapurkar N., Reddy J., Chaudhary P.M., Gazdar A.F. Apoptosis and lung cancer: a review. J. Cell. Biochem. 2003, 88:885-898.
19. Smith C.I., Islam T.C., Mattsson P.T., Mohamed A.J., Nore B.F., Vihinen M. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001, 23:436-446.
20. Tamagnone L., Lahtinen I., Mustonen T., Virtaneva K., Francis F., Muscatelli F., Alitalo R., Smith C.I., Larsson C., Alitalo K. BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene 1994, 9:3683-3688.
21. Wang D.G., Johnston C.F., Sloan J.M., Buchanan K.D. Expression of bcl-2 in lung neuroendocrine tumors: comparison with p53. J. Pathol. 1998, 184:247-251.
22. Wen X., Lin H.H., Shih H.M., Kung H.J., Ann D.K. Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J. Biol. Chem. 1999, 274:38204-38210.
23. Xue L.Y., Qiu Y., He J., Kung H.J., Oleinick N.L. Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 1999, 18:3391-3398.